Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel J Kass

Showing results (1-10 of 96) with videos related to

Pageof 10
Sort By:
Respirology (Carlton, Vic.)|March 20, 2019
Treatment of interstitial lung disease: Do the ends justify the means?Daniel J Kass
Cytokine|July 1, 2011
Cytokine-like factor 1 (CLF1): life after development?Daniel J Kass
American Journal of Respiratory Cell and Molecular Biology|December 15, 2022
Integrating the Integrated Stress ResponseHarinath Bahudhanapati, Daniel J Kass
Thorax|October 30, 2016
Time to share: lessons from post hoc analyses of IPF trialsDaniel J Kass, Naftali Kaminski
Respirology (Carlton, Vic.)|September 18, 2025
Clean Sweep or Just a Wash? What BAL Lymphocytes Really Say About Steroid Outcomes in ILDJasmine Vakhshoorzadeh, Daniel J Kass
Clinical and Translational Science|October 28, 2011
Evolving genomic approaches to idiopathic pulmonary fibrosis: moving beyond genesDaniel J Kass, Naftali Kaminski
American Journal of Respiratory Cell and Molecular Biology|July 1, 2017
Unwinding the Collagen Fibrils: Elucidating the Mechanism of Pirfenidone and Nintedanib in Pulmonary FibrosisHarinath Bahudhanapati, Daniel J Kass
American Journal of Respiratory and Critical Care Medicine|December 2, 2016
Reply: Promise and Limitations of Relaxin-based Therapies in Chronic Fibrotic Lung DiseasesJiangning Tan, Daniel J Kass
Annals of the American Thoracic Society|April 2, 2019
Diagnosis from Afar: Is Remote Multidisciplinary Discussion Appropriate for Interstitial Lung Disease Care?Eleanor Valenzi, Daniel J Kass
American Journal of Respiratory and Critical Care Medicine|May 5, 2026
Is there more to change in forced vital capacity in pulmonary fibrosis trials?Adi Andrei, Daniel J Kass
Pageof 10

Showing results (1-10 of 96) with videos related to

Sort By:
Pageof 10
Respirology (Carlton, Vic.)|March 20, 2019
Treatment of interstitial lung disease: Do the ends justify the means?Daniel J Kass
Cytokine|July 1, 2011
Cytokine-like factor 1 (CLF1): life after development?Daniel J Kass
American Journal of Respiratory Cell and Molecular Biology|December 15, 2022
Integrating the Integrated Stress ResponseHarinath Bahudhanapati, Daniel J Kass
Thorax|October 30, 2016
Time to share: lessons from post hoc analyses of IPF trialsDaniel J Kass, Naftali Kaminski
Respirology (Carlton, Vic.)|September 18, 2025
Clean Sweep or Just a Wash? What BAL Lymphocytes Really Say About Steroid Outcomes in ILDJasmine Vakhshoorzadeh, Daniel J Kass
Clinical and Translational Science|October 28, 2011
Evolving genomic approaches to idiopathic pulmonary fibrosis: moving beyond genesDaniel J Kass, Naftali Kaminski
American Journal of Respiratory Cell and Molecular Biology|July 1, 2017
Unwinding the Collagen Fibrils: Elucidating the Mechanism of Pirfenidone and Nintedanib in Pulmonary FibrosisHarinath Bahudhanapati, Daniel J Kass
American Journal of Respiratory and Critical Care Medicine|December 2, 2016
Reply: Promise and Limitations of Relaxin-based Therapies in Chronic Fibrotic Lung DiseasesJiangning Tan, Daniel J Kass
Annals of the American Thoracic Society|April 2, 2019
Diagnosis from Afar: Is Remote Multidisciplinary Discussion Appropriate for Interstitial Lung Disease Care?Eleanor Valenzi, Daniel J Kass
American Journal of Respiratory and Critical Care Medicine|May 5, 2026
Is there more to change in forced vital capacity in pulmonary fibrosis trials?Adi Andrei, Daniel J Kass
Pageof 10